JOURNAL ARTICLE

The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a's role in treating mycosis fungoides/Sézary syndrome.

  • Published In: British Journal of Dermatology, 2024, v. 191, n. 3. P. 321 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Stadler, Rudolf 3 of 3

Abstract

The article discusses the use of pegylated interferon α-2a (PEG-IFN-α) in the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), which are types of cutaneous T-cell lymphoma (CTCL). The immune system plays a role in restraining tumor growth in the early stages of CTCL, but as the disease progresses, there is a shift towards immune evasion and tumor advancement. Recombinant IFN-α has been used effectively in the treatment of CTCL, and PEG-IFN-α has emerged as an alternative therapy. A retrospective study analyzed the response and adverse events associated with PEG-IFN-α and found an overall response rate of 53% and a time to next treatment of 9.2 months. PEG-IFN-α is recommended to be used in combination with skin-directed therapies. Overall, PEG-IFN-α represents an innovative treatment option for patients with early and advanced CTCL. [Extracted from the article]

Additional Information

  • Source:British Journal of Dermatology. 2024/09, Vol. 191, Issue 3, p321
  • Document Type:Article
  • Subject Area:Anatomy and Physiology
  • Publication Date:2024
  • ISSN:0007-0963
  • DOI:10.1093/bjd/ljae188
  • Accession Number:179059395
  • Copyright Statement:Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.